[Scientific Reports] Human CB-MSCs were isolated and characterized using flow cytometry. Cell differentiation has been induced by combining retinoic acid and sonic hedgehog in a two-step protocol for 14 days.
[Seminars in Cell & Developmental Biology] Scientists examine current knowledge of early human placental development, discuss the critical role of the maternal endometrium and of the fetal-maternal dialogue in pregnancy success, and they explore the latest models of trophoblast and endometrial stem cells.
[Essent Biologicsâ„¢ (PR NewsWire, Inc.)] Essent Biologicsâ„¢ announced the launch of its human mesenchymal stem cells for regenerative medicine, biopharmaceutical and cell therapy research.
[Nature Genetics] By monitoring epigenomes, transcriptomes and lineages with single-cell resolution, scientists showed that the repressive histone mark trimethylation of histone H3 at lysine 27 (H3K27me3) regulated cell fate at the onset of chemotherapy.
[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified a membrane receptor for progesterone/17-hydroxyprogesterone and delineated the mechanisms by which GPR126 participated in potential tumor progression in TNBC.
[npj Breast Cancer] Researchers identified 1127 lncRNAs differentially expressed in late-stage relapse (LSR) breast cancer (BC) via transcriptome sequencing and analysis of 72 early-stage and 24 LSR BC patient tumors.
[University College London (UCL)] Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.
[Anixa Biosciences, Inc. (PR Newswire)] Anixa Biosciences, Inc. announced updated positive survival observations from its ongoing Phase I clinical trial of liraltagene autoleucel, or lira-cel, a follicle-stimulating hormone receptor-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.
[Science Immunology] Scientists demonstrated that fractalkine-conjugated mRNA lipid nanoparticles can specifically target and deliver mRNA to CX3CR1+ effector CD8 T cells in vitro and in vivo.